Thus, whilst pharmacological levels of GLP-1 or its DPP-IV resistant analogues undisputedly promote insulin secretion in type-2 diabetic patients, raising GIP levels is widely reported to be ineffective (Holst, 2007; Nauck et al., 1993). This evidence concerns the gene INS and type 2 diabetes mellitus.